Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Table: Axios Visuals

Four vaccines for the novel coronavirus are now in late-stage testing in people in the United States.

Driving the news: Johnson & Johnson announced yesterday it began a phase 3 clinical trial of its COVID-19 vaccine candidate.

Here are key details about the vaccines:

1. Johnson & Johnson vaccine (Ad.26.COV2.S):

  • How it works: A non-infectious adenovirus — a common cold virus — is used to deliver a gene from the novel coronavirus to human cells and produce copies of the SARS-CoV-2 protein, potentially priming immune cells to fight infection.
  • An Ebola vaccine granted approval in Europe earlier this year uses the same technology.
  • The vaccine is being tested as a single dose and can be stored refrigerated for at least three months, potentially alleviating some of the concerns about the logistics of distribution
  • The U.S. government has advance purchased 100 million doses of the vaccine if it is approved, with the option to buy 200 million more.

2. Moderna vaccine (mRNA-1273):

  • How it works: Messenger RNA — genetic material carrying information about a viral protein — is delivered to cells that produce the protein, which the immune system is then trained to recognize.
  • RNA vaccines are a newer technology, favored for their potential speed in development, but none have been approved for humans — for any virus.
  • The vaccine is being given in two doses and is stored frozen.
  • Moderna has a deal to sell 100 million doses of its potential vaccine to the U.S. government, which can buy an additional 400 million doses.

3. Pfizer vaccine (BNT162b2):

  • How it works: This vaccine is also a mRNA vaccine being tested as two doses.
  • It currently requires storage at -70°C. A company spokesperson says they've developed dry ice shippers to maintain that temperature for up to 10 days and that they hope to have a formulation that will be stored at -2 to -8°C by mid-2022.
  • Pfizer has an initial agreement with the U.S. government for 100 million doses if the vaccine is approved, with an option for 500 million more doses.

4. AstraZeneca/Oxford University vaccine (AZD1222):

  • How it works: Similar to the Johnson & Johnson vaccine, this candidate is a viral vector vaccine but uses a different adenovirus.
  • The vaccine's trial in the U.S. is currently paused after a "suspected adverse event" in a participant in a U.K. trial of the vaccine.
  • It is being given in two doses and the company is studying its storage and distribution requirements. A spokesperson for AstraZeneca tells Axios they expect it will require refrigeration.
  • AstraZeneca's agreement with the U.S. government is "inclusive of the development, production and delivery of 300m [million] doses of the potential vaccine, which includes the Phase III clinical trial," they added.

The big picture: There are 212 COVID-19 vaccines in development worldwide, with at least nine in phase III clinical trials, according to the Milken Institute.

  • Experts say several vaccines will be required to fight this pandemic.

What to watch: As the world awaits results from these trials, some researchers are calling for the studies to be modified to ensure they are testing if the vaccine protects against moderate and severe disease, as well as covering all people.

  • Amidst growing public skepticism and distrust of vaccines, the FDA is planning to tighten requirements for assessing a vaccine's safety and effectiveness, the Washington Post reported.

Go deeper

Dec 31, 2020 - Health

WHO lists Pfizer COVID-19 vaccine for emergency use

A healthcare worker giving a patient a dose of Pfizer-BioNTech's coronavirus vaccine in Florida on Dec. 30. Photo: Marco Bello/Anadolu Agency via Getty Images

The World Health Organization on Thursday listed Pfizer-BioNTech's COVID-19 vaccine for emergency use.

Why it matters: The approval — the WHO's first for a coronavirus vaccine — may allow some countries to expedite their own regulatory approval processes so they can import and administer the vaccine quicker, the WHO said.

Updated 34 mins ago - Politics & Policy

Omicron dashboard

Illustration: Brendan Lynch/Axios

  1. Health: Pfizer and Moderna boosters overwhelmingly prevent Omicron hospitalizations, CDC finds — Omicron pushes COVID deaths toward 2,000 per day — The pandemic-proof health care giant.
  2. Vaccines: The case for Operation Warp Speed 2.0 — Starbucks drops worker vaccine or test requirement after SCOTUS ruling — Kids' COVID vaccination rates are particularly low in rural America.
  3. Politics: Biden concedes U.S. should have done more testing — Arizona says it "will not be intimidated" by Biden on anti-mask school policies.
  4. World: American Airlines flight to London forced to turn around over mask dispute — WHO: COVID health emergency could end this year — Greece imposes vaccine mandate for people 60 and older — Austria approves COVID vaccine mandate for adults.
  5. Variant tracker
Dec 31, 2020 - Health

China approves state-owned Sinopharm vaccine

Sinopharm vaccine. Photo Illustration: Pavlo Gonchar/SOPA Images/LightRocket via Getty Images

Health regulators in China said Thursday they have approved the country's first homegrown COVID-19 vaccine, developed by the state-owned pharmaceutical company Sinopharm, for general use, AP reports.

Why it matters: Like the vaccine developed by AstraZeneca and Oxford University, Sinopharm's shot is said to be cheaper and easier to store than Pfizer or Moderna's vaccines.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!